Logo image of OCUL

OCULAR THERAPEUTIX INC (OCUL) Stock Fundamental Analysis

NASDAQ:OCUL - Nasdaq - US67576A1007 - Common Stock - Currency: USD

7.3  +0.08 (+1.18%)

After market: 7.3 0 (0%)

Fundamental Rating

3

OCUL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. OCUL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OCUL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

OCUL had negative earnings in the past year.
OCUL had a negative operating cash flow in the past year.
In the past 5 years OCUL always reported negative net income.
OCUL had a negative operating cash flow in each of the past 5 years.
OCUL Yearly Net Income VS EBIT VS OCF VS FCFOCUL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

OCUL has a Return On Assets (-47.48%) which is in line with its industry peers.
With a Return On Equity value of -72.47%, OCUL perfoms like the industry average, outperforming 47.98% of the companies in the same industry.
Industry RankSector Rank
ROA -47.48%
ROE -72.47%
ROIC N/A
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
OCUL Yearly ROA, ROE, ROICOCUL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

The Gross Margin of OCUL (90.67%) is better than 92.93% of its industry peers.
In the last couple of years the Gross Margin of OCUL has grown nicely.
OCUL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
OCUL Yearly Profit, Operating, Gross MarginsOCUL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

OCUL does not have a ROIC to compare to the WACC, probably because it is not profitable.
OCUL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for OCUL has been increased compared to 5 years ago.
OCUL has a better debt/assets ratio than last year.
OCUL Yearly Shares OutstandingOCUL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
OCUL Yearly Total Debt VS Total AssetsOCUL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

OCUL has an Altman-Z score of 1.21. This is a bad value and indicates that OCUL is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.21, OCUL is doing good in the industry, outperforming 64.14% of the companies in the same industry.
A Debt/Equity ratio of 0.26 indicates that OCUL is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.26, OCUL is in line with its industry, outperforming 44.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 1.21
ROIC/WACCN/A
WACC10.94%
OCUL Yearly LT Debt VS Equity VS FCFOCUL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 10.22 indicates that OCUL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 10.22, OCUL belongs to the top of the industry, outperforming 83.84% of the companies in the same industry.
A Quick Ratio of 10.14 indicates that OCUL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.14, OCUL belongs to the top of the industry, outperforming 83.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.22
Quick Ratio 10.14
OCUL Yearly Current Assets VS Current LiabilitesOCUL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

OCUL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.30%, which is quite impressive.
The Revenue has decreased by -0.33% in the past year.
The Revenue has been growing by 72.02% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)22.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-27.59%

3.2 Future

OCUL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.60% yearly.
The Revenue is expected to grow by 60.73% on average over the next years. This is a very strong growth
EPS Next Y1.04%
EPS Next 2Y0.01%
EPS Next 3Y6.11%
EPS Next 5Y21.6%
Revenue Next Year-13.36%
Revenue Next 2Y-0.89%
Revenue Next 3Y22.11%
Revenue Next 5Y60.73%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
OCUL Yearly Revenue VS EstimatesOCUL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
OCUL Yearly EPS VS EstimatesOCUL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OCUL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OCUL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCUL Price Earnings VS Forward Price EarningsOCUL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCUL Per share dataOCUL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.01%
EPS Next 3Y6.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OCUL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCULAR THERAPEUTIX INC

NASDAQ:OCUL (5/23/2025, 8:43:19 PM)

After market: 7.3 0 (0%)

7.3

+0.08 (+1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-05 2025-05-05/bmo
Earnings (Next)08-04 2025-08-04/amc
Inst Owners85.26%
Inst Owner Change0.5%
Ins Owners2.7%
Ins Owner Change24.53%
Market Cap1.16B
Analysts86.67
Price Target17.8 (143.84%)
Short Float %8.37%
Short Ratio7.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.8%
Min EPS beat(2)-26.63%
Max EPS beat(2)-12.97%
EPS beat(4)1
Avg EPS beat(4)-10.94%
Min EPS beat(4)-26.63%
Max EPS beat(4)10.95%
EPS beat(8)3
Avg EPS beat(8)-32.19%
EPS beat(12)4
Avg EPS beat(12)-27.48%
EPS beat(16)8
Avg EPS beat(16)-3.13%
Revenue beat(2)0
Avg Revenue beat(2)-20.17%
Min Revenue beat(2)-37.69%
Max Revenue beat(2)-2.66%
Revenue beat(4)1
Avg Revenue beat(4)-12.56%
Min Revenue beat(4)-37.69%
Max Revenue beat(4)1.86%
Revenue beat(8)2
Avg Revenue beat(8)-8.17%
Revenue beat(12)3
Avg Revenue beat(12)-8.64%
Revenue beat(16)4
Avg Revenue beat(16)-7.95%
PT rev (1m)0%
PT rev (3m)-4.21%
EPS NQ rev (1m)-19.22%
EPS NQ rev (3m)-31.63%
EPS NY rev (1m)-17.41%
EPS NY rev (3m)-34.82%
Revenue NQ rev (1m)-22.27%
Revenue NQ rev (3m)-21.28%
Revenue NY rev (1m)-21.89%
Revenue NY rev (3m)-23.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.5
P/FCF N/A
P/OCF N/A
P/B 4.37
P/tB 4.37
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-1.47
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS0.37
BVpS1.67
TBVpS1.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.48%
ROE -72.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.68%
FCFM N/A
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
F-Score2
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.1%
Cap/Sales 4.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.22
Quick Ratio 10.14
Altman-Z 1.21
F-Score2
WACC10.94%
ROIC/WACCN/A
Cap/Depr(3y)138.13%
Cap/Depr(5y)98.78%
Cap/Sales(3y)6.55%
Cap/Sales(5y)5.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
EPS Next Y1.04%
EPS Next 2Y0.01%
EPS Next 3Y6.11%
EPS Next 5Y21.6%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-27.59%
Revenue Next Year-13.36%
Revenue Next 2Y-0.89%
Revenue Next 3Y22.11%
Revenue Next 5Y60.73%
EBIT growth 1Y-123.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.35%
EBIT Next 3Y0.4%
EBIT Next 5Y25.96%
FCF growth 1Y-118.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-138.58%
OCF growth 3YN/A
OCF growth 5YN/A